Lynch Syndrome and Women's Cancers: Endometrial and Ovarian Risk, Hysterectomy and Pregnancy

Endometrial cancer is often the first Lynch-related cancer in a woman. Clinic-based estimates span 25–55%, while PLSD gives 37.0–48.9% by age 75 for MLH1, MSH2 and MSH6 and 12.8% for PMS2. PLSD 2023 reported median diagnosis near 52 for MLH1 and MSH2 and 60 for MSH6. ^[1,4,18]

Risk estimates by gene, source and age

The Dutch cohort called its estimate lower than previously reported and identified ascertainment bias as a possible reason. The 71% MSH6 figure is an outlier from the Kluk 2026 review rather than a value to substitute for PLSD. MSH6 and PMS2 onset intervals were wide. ^{[1,4,6,20,21]}

Symptoms and surveillance limits

Abnormal vaginal bleeding, pelvic pain or pressure, and abnormal discharge need prompt clinical assessment (MD Anderson; Mayo Clinic). Endometrial biopsy every one to two years from ages 30 to 35 can be considered under ACOG and NCCN guidance as summarised by Underkofler and Ring. Transvaginal ultrasound detects less disease and is not recommended before menopause. ^{[8,9,10,16,18]}

Before surgery, combined or progestin-only hormonal contraception used for at least a year was associated with 61% lower endometrial cancer risk in one retrospective Lynch cohort; a progestin IUD is another option, but Lynch-specific data are limited. Ten-year crude survival after endometrial cancer was 92% in PLSD 2023. Read about survival after a Lynch syndrome cancer. ^[4,8,16]

Endometrial tumours can undergo mismatch-repair immunohistochemistry or microsatellite-instability analysis. This tumour testing for Lynch syndrome is different from germline testing.

Ovarian cancer risk in Lynch syndrome is lower than endometrial risk and depends on the gene. PLSD reported 10%, 17% and 13% by age 75 for MLH1, MSH2 and MSH6, with no clearly raised PMS2 risk. Lynch-associated ovarian cancer is usually diagnosed around ages 43 to 51 and often at stage I or II. ^[1,2,7]

These figures differ because methods, eras and family selection differ; they are shown rather than collapsed into one “lifetime” number. Ryan et al. found endometrioid histology in 53% and stage I or II disease in 85%. High-grade serous disease is uncommon. Lynch-associated ovarian cancer is biologically different from BRCA1 and BRCA2 and ovarian cancer. ^{[2,4,7,8,19,22]}

Persistent bloating, pelvic or abdominal pain, early fullness and urinary urgency need clinical assessment. PLSD reported ten-year crude survival of 85%. SGO advises offering genetic testing to every woman with ovarian cancer. The reviewed evidence does not provide a directly comparable five-year survival figure for this page. ^[4,17,19]

Risk-reducing hysterectomy removes the uterus and prevents endometrial cancer. Schmeler et al. reported no endometrial cancers among 61 carriers after hysterectomy, against 33% of 210 controls. Guidance usually places discussion after childbearing and around ages 40 to 45. PLSD 2021 found little benefit from risk-reducing surgery before 40. ^[3,5,8,9]

Gene- and age-specific benefit before age 50

PLSD concluded that little benefit is gained by operating before age 40 and that premenopausal BSO in MSH6 and PMS2 carriers had no measurable mortality benefit. These are population estimates, not an instruction for an individual. ^[3]

Whether and when to remove the ovaries

NCCN guidance, as summarised by Underkofler and Ring rather than read directly for this page, individualises ovary removal for MLH1 and MSH2/EPCAM, finds insufficient evidence for MSH6, and says PMS2 carriers may reasonably choose not to have oophorectomy. Salpingectomy is recommended with hysterectomy. ACOG says to discuss removal by the mid-40s; other guidance commonly gives 40 to 45 after family completion, with some UK materials giving 35 to 40. ^[8,9,10]

Gene-specific context is available in the MLH1 risk profile, MSH2 risk profile, MSH6 risk profile and PMS2 risk profile.

Cancer after surgery, recovery and menopause

Schmeler et al. observed no endometrial, ovarian or primary peritoneal cancers among 61 hysterectomy and 47 BSO participants; matched controls had 33% endometrial and 5% ovarian cancer. Eikenboom et al. found one incidental ovarian cancer in a prophylactic specimen and one endometrial carcinoma in a hysterectomy specimen. These data do not mean every related cancer risk becomes zero. ^[5,6]

Recovery is commonly estimated at six to eight weeks. A 40-woman French series reported more complications than expected in the general population and advised caution. Premenopausal BSO causes immediate surgical menopause, affecting bone, cardiovascular, cognitive and sexual health; the CDC also publishes a first-person surgical-menopause story. Estrogen-only HRT is generally considered safe after hysterectomy and BSO, although it has not been studied directly in Lynch syndrome; 15 of 21 PLSD centres offered it between ages 35 and 55. ^{[8,14,15,23,24]}

This is a personal decision with a gynaecologic oncologist, and there is time to consider preventive options. Read more about survival after a Lynch syndrome cancer. ^[9]

Each child of a parent with Lynch syndrome has a 50% chance of inheriting the variant from either parent. Surgery is usually delayed until childbearing is complete. Options to avoid passing on a variant include preimplantation genetic testing, donor eggs and adoption. Many people also have children without fertility technology. ^[9,17,18]

If both partners carry a pathogenic variant in the same mismatch-repair gene, a child can inherit constitutional mismatch repair deficiency, a rare recessive childhood-onset condition. A genetic counsellor can review this risk. ACOG states there is no medical reason to test children for an adult-onset Lynch variant before age 18. ^[9,17]

In a small 2011 study of 161 people, 80% worried about their children's risk, 9% said family history affected whether they would have children and 20% of women would consider earlier childbearing so surgery could happen sooner. These older attitude data do not predict an individual decision. ^[13]

A UK decision aid advises against daily aspirin after 30 weeks of pregnancy and while breastfeeding. See aspirin and surveillance and discuss medicines with the pregnancy-care team. None of the sources reviewed for this page reports pregnancy outcomes for women with Lynch syndrome; the page therefore does not claim that Lynch syndrome does or does not affect fertility. ^[27]

Lynch syndrome questions often combine population estimates with personal decisions. The short answers below retain the gene, age and source where a number is used. They cannot determine an individual surgery, screening or pregnancy plan, which needs genetic counselling and clinical review.

Surgery timing in Lynch syndrome depends on the gene, so a gene-level clinical result matters. PMS2 estimates differ substantially from MLH1 and MSH2 estimates. Human Longevity describes its $599 whole-genome service as including a cancer risk assessment, but its exact coverage of MLH1, MSH2, MSH6, PMS2 and EPCAM remains unconfirmed. It does not detect existing cancer.

A finding is a starting point. Confirmatory clinical testing and a genetic counsellor come before surveillance, fertility or surgery decisions. This page neither recommends nor discourages surgery. Compare the four gene profiles above and BRCA1 and BRCA2 and ovarian cancer, where ovarian tumour biology and prevention decisions differ.

See what the $599 genome service includes. The product page, not this evidence section, is the source for current service scope and pricing.